Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed 150 IU recombinant gonadotropin with fixed day-6 GnRH antagonist protocol in high-responder IVF/ICSI patients with AMH >4 ng/mL
ACTRN12614000242628Phase 4Completed
- Sponsor
- Recai Pabuccu, Proff., M.D.
- Start
- Mar 2014
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of relugolix in infertility, sponsored by Recai Pabuccu, Proff., M.D. Primary endpoint: Ovarian hyperstimulation syndrome incidence. Started Mar 2014; status: completed.
02
Drugs
relugolix
03
Conditions
infertility
Beyond the preview
Go deeper on ACTRN12614000242628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000242628.